Company Overview
About CUTISS
CUTISS is a Swiss clinical-stage biotechnology company founded in 2017 as a spin-off from the University Children's Hospital Zurich, focused on developing personalized bioengineered skin grafts for patients with large skin defects caused by severe burns, rare congenital skin diseases, and traumatic wounds. The company's lead product, denovoSkin, is a dermo-epidermal skin graft manufactured by combining a small biopsy of a patient's own skin cells with a proprietary hydrogel scaffold — which is then cultured to grow a full-thickness skin equivalent containing both the dermis (dermal layer) and epidermis (outer layer). Because the graft uses the patient's own cells, it avoids immune rejection without the need for immunosuppression.
Business Model & Competitive Advantage
denovoSkin addresses a critical limitation of current burn and skin defect treatment: split-thickness autografting — the standard of care — requires harvesting skin from an unaffected area of the patient's body (the donor site), which creates additional wounds, limits graft size by available donor skin, and can leave permanent scarring at donor sites. CUTISS's bioengineered approach generates sufficient graft area from a small biopsy, reducing the number of autograft surgeries needed and the associated donor-site morbidity. The company has raised over CHF 30 million in funding from Swiss and European investors and is advancing denovoSkin toward European Medicines Agency (EMA) marketing authorization.
Competitive Landscape 2025–2026
CUTISS operates in the emerging advanced therapy medicinal products (ATMP) sector, alongside companies such as Avita Medical (ReCell), Stratatech, and Integra LifeSciences in the broader wound care market. CUTISS differentiates through its full-thickness dermo-epidermal construct — which more closely resembles natural skin than split-thickness grafts or dermal substitutes alone — and its personalized, cell-based manufacturing process that makes it an autologous therapy with strong safety credentials.
Key Differentiators
Emerging Innovator
CUTISS is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Compare CUTISS with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from CUTISS? Verify your company email to claim this profile and keep its description, products, and FAQs up to date.
Claim CUTISS Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention CUTISS vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →